Literature DB >> 18161700

Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis.

Amir A Qamar1, Norman D Grace, Roberto J Groszmann, Guadalupe Garcia-Tsao, Jaime Bosch, Andrew K Burroughs, Rie Maurer, Ramon Planas, Angels Escorsell, Juan Carlos Garcia-Pagan, David Patch, Daniel S Matloff, Robert Makuch.   

Abstract

UNLABELLED: Current guidelines recommend esophagogastroduodenoscopy (EGD) in patients with cirrhosis to screen for gastroesophageal varices (GEV). Thrombocytopenia has been proposed as a noninvasive test to predict the presence of GEV. There is no agreement regarding a specific platelet count (PLT) that can reliably predict GEV. The present longitudinal study aims to (1) further investigate the relationship between varices and PLT at the time of endoscopy, (2) investigate whether changes in PLT from the baseline over time can predict the development of GEV, and (3) investigate whether changes in PLT correlate with the hepatic venous pressure gradient (HVPG). A secondary analysis was conducted for 213 subjects with compensated cirrhosis with portal hypertension but without GEV enrolled in a randomized, placebo-controlled, double-blind trial of a nonselective beta-blocker used to prevent GEV. PLTs were obtained every 3 months, and HVPG measurements and EGD were done annually. The PLTs were compared between subjects who did and did not develop GEV. In a median follow-up of 54.9 months, 84 patients developed GEV. PLT was greater than 150,000 in 15% of patients at the development of GEV. A receiver operating curve did not show any PLT with high sensitivity or specificity for the presence of GEV. Subjects with clinically insignificant portal hypertension (HVPG < 10 mm Hg) whose PLT remained greater than 100,000 had a 2-fold reduction in the occurrence of GEV (P = 0.0374). A significant correlation was found between HVPG and PLT at the baseline, year 1, and year 5 (P < 0.0001).
CONCLUSION: Cross-sectional or longitudinal evaluations of PLTs are inadequate noninvasive markers for GEV. Patients with mild portal hypertension whose PLT remains greater than 100,000 have significantly less risk of GEV. Although HVPG correlates somewhat with PLT, changes in PLT cannot be used as a surrogate for HVPG changes.

Entities:  

Mesh:

Year:  2008        PMID: 18161700     DOI: 10.1002/hep.21941

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

Review 1.  Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.

Authors:  Agostino Colli; Juan Cristóbal Gana; Jason Yap; Thomasin Adams-Webber; Natalie Rashkovan; Simon C Ling; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2017-04-26

2.  Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.

Authors:  Robert J Fontana; Arun J Sanyal; Marc G Ghany; William M Lee; Andrea E Reid; Deepa Naishadham; Gregory T Everson; Jeffrey A Kahn; Adrian M Di Bisceglie; Gyongyi Szabo; Timothy R Morgan; James E Everhart
Journal:  Gastroenterology       Date:  2010-03-06       Impact factor: 22.682

3.  Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis.

Authors:  Naoki Morishita; Naoki Hiramatsu; Tsugiko Oze; Naoki Harada; Ryoko Yamada; Masanori Miyazaki; Takayuki Yakushijin; Takuya Miyagi; Yuichi Yoshida; Tomohide Tatsumi; Tatsuya Kanto; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2013-09-05       Impact factor: 7.527

4.  Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis.

Authors:  Parastoo Jangouk; Laura Turco; Ana De Oliveira; Filippo Schepis; Erica Villa; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2017-03-07       Impact factor: 5.828

5.  Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.

Authors:  Amir A Qamar; Norman D Grace; Roberto J Groszmann; Guadalupe Garcia-Tsao; Jaime Bosch; Andrew K Burroughs; Cristina Ripoll; Rie Maurer; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Robert Makuch; Gabriel Rendon
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-10       Impact factor: 11.382

6.  Platelet count to spleen diameter ratio for the diagnosis of esophageal varices: Is it feasible?

Authors:  Waqas Wahid Baig; M V Nagaraja; Muralidhar Varma; Ravindra Prabhu
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

7.  Noninvasive methods for prediction of esophageal varices in pediatric patients with portal hypertension.

Authors:  Marina Rossato Adami; Cristina Targa Ferreira; Carlos Oscar Kieling; Vania Hirakata; Sandra Maria Gonçalves Vieira
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

Review 8.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 9.  Clinical Assessment and Management of Portal Hypertension.

Authors:  Jacob Kibrit; Ruben Khan; Barbara H Jung; Sean Koppe
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

10.  The predictors of the presence of varices in patients with primary sclerosing cholangitis.

Authors:  Sombat Treeprasertsuk; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders; Keith D Lindor
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.